Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) have been assigned an average rating of “Hold” from the twelve brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $17.00.

Several analysts have commented on the company. Zacks Investment Research downgraded PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. ValuEngine downgraded PTC Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 7th. William Blair assumed coverage on PTC Therapeutics in a research note on Wednesday, August 23rd. They set a “market perform” rating and a $17.00 price objective for the company. BidaskClub downgraded PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 4th. Finally, J P Morgan Chase & Co downgraded PTC Therapeutics from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $23.00 to $15.00 in a research note on Monday, October 9th.

ILLEGAL ACTIVITY NOTICE: “PTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of “Hold” from Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/22/ptc-therapeutics-inc-ptct-receives-consensus-recommendation-of-hold-from-analysts.html.

Shares of PTC Therapeutics (NASDAQ:PTCT) traded up 0.68% on Friday, reaching $17.79. The company had a trading volume of 683,912 shares. PTC Therapeutics has a 52 week low of $4.03 and a 52 week high of $22.00. The firm’s market capitalization is $736.31 million. The company’s 50-day moving average price is $19.24 and its 200 day moving average price is $16.77.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.45. The firm had revenue of $47.96 million during the quarter, compared to the consensus estimate of $28.78 million. PTC Therapeutics had a negative return on equity of 81.84% and a negative net margin of 88.43%. The firm’s revenue was up 206.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.14) EPS. On average, analysts expect that PTC Therapeutics will post ($2.35) EPS for the current year.

Hedge funds have recently modified their holdings of the company. Alps Advisors Inc. raised its stake in shares of PTC Therapeutics by 5.6% during the 2nd quarter. Alps Advisors Inc. now owns 31,191 shares of the biopharmaceutical company’s stock worth $572,000 after buying an additional 1,667 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of PTC Therapeutics by 75.1% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 42,593 shares of the biopharmaceutical company’s stock worth $781,000 after buying an additional 18,273 shares in the last quarter. Nomura Holdings Inc. raised its stake in shares of PTC Therapeutics by 28.7% during the 2nd quarter. Nomura Holdings Inc. now owns 50,672 shares of the biopharmaceutical company’s stock worth $928,000 after buying an additional 11,300 shares in the last quarter. American International Group Inc. raised its stake in shares of PTC Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 20,480 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 1,355 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of PTC Therapeutics during the 2nd quarter worth approximately $445,000. 81.30% of the stock is owned by institutional investors and hedge funds.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.